2021
DOI: 10.1038/s41591-021-01378-7
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence

Abstract: mazonas state reported the first confirmed SARS-CoV-2 case in Manaus, the state capital, in March 2020 in a traveler returning from Europe 1 . By late February 2021, >306,000 laboratory-confirmed cases and more than 10,400 deaths in Amazonas had been reported 2 . The COVID-19 epidemic in Amazonas is, at the time of writing, characterized by two exponentially growing curves of cases (Fig. 1a). Epidemiological data from surveillance of severe acute respiratory illness (SARI) and burials indicate that the first w… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

12
257
4
10

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 292 publications
(283 citation statements)
references
References 44 publications
12
257
4
10
Order By: Relevance
“…They found that NAbTs were 5.8-fold reduced against B.1.617.2 relative to wild type on a similar order to the reduction observed against B.1.351 [224]. B.1.617 partially evaded neutralization by the antibodies induced through natural infection or immunization with the BNT162b2 and mRNA-1273 vaccine, while sera from individuals having received one dose of AstraZeneca/Oxford (ChAdOx1) vaccine barely inhibited B.1.617.2 [214][215][216]. Convalescent sera from infected patients and from recipients of BBV152 (Covaxin) were able to neutralize B.1.617 partially, but the effect was robust, as seen with mRNA vaccines [214].…”
Section: P1 Variant (Gamma Variant)mentioning
confidence: 59%
See 1 more Smart Citation
“…They found that NAbTs were 5.8-fold reduced against B.1.617.2 relative to wild type on a similar order to the reduction observed against B.1.351 [224]. B.1.617 partially evaded neutralization by the antibodies induced through natural infection or immunization with the BNT162b2 and mRNA-1273 vaccine, while sera from individuals having received one dose of AstraZeneca/Oxford (ChAdOx1) vaccine barely inhibited B.1.617.2 [214][215][216]. Convalescent sera from infected patients and from recipients of BBV152 (Covaxin) were able to neutralize B.1.617 partially, but the effect was robust, as seen with mRNA vaccines [214].…”
Section: P1 Variant (Gamma Variant)mentioning
confidence: 59%
“…The P.1 variant has accumulated 12 mutations in the spike protein, including the N501Y mutation, which is also present in B.1.1.7 and B.1.351, while L18F, K417T, E484K and D614G mutations are shared with the B.1.351 variant (Figure 2B). Overall, P.1 contains 12 spike mutations in addition to D614G, including K417T, E484K and N501Y in the RBD, L18F, T20N, P26S, D138Y and R190S in the NTD, and H655Y near the furin cleavage site [214][215][216].…”
Section: P1 Variant (Gamma Variant)mentioning
confidence: 99%
“…It has already been described that Gamma lineage can escape of the neutralization antibodies acquired by infection or immunization with previously circulating viral variants (de Souza et al, 2021) . As well, it was suggested that the Gamma is more transmissible than previously circulating lineages (Naveca et al, 2021) . These facts, in addition to the lack an e cient social distancing and other prevention measures probably caused the high numbers observed in this big SARS-CoV-2 wave.…”
Section: Discussionmentioning
confidence: 99%
“…Shortly thereafter, it was suggested that the Gamma is more transmissible. This fact in addition to the lack of e cient social distancing and other prevention measures probably caused the high hospitalizations (Naveca et al, 2021) . Also, it was observed rapid dissemination to other Brazilian regions as in Southern of Brazil where the Gamma variant would have already been identi ed, on November 30 This same phenomenon, characterized by a rapid spread had already been observed prior to March 2020.…”
Section: Introductionmentioning
confidence: 99%
“…The P.1 variant has accumulated 12 mutations in the spike protein including the N501Y mutation, which is also present in B.1.1.7 and B.1.351, while L18F, K417T, E484K, and D614G mutations are shared with the B.1.351 variant (Figure 2B). Overall, P.1 contains 12 spike mutations in addition to D614G, including K417T, E484K, and N501Y in the RBD, L18F, T20N, P26S, D138Y and R190S in the NTD, and H655Y near the furin cleavage site [204][205][206].…”
Section: Sars-cov-2 Variantsmentioning
confidence: 99%